Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 5, 2009 Dan Caplinger	Where the Real Value Is Now Here's a sample of stocks that look relatively cheap compared with their peers and the overall market: Chevron... Oracle... FMC... Raytheon... Kraft Foods...
The Motley Fool July 6, 2010 Rick Aristotle Munarriz	Beware of Cheap Stocks Just because a stock price falls, that doesn't mean you got a better deal.
The Motley Fool January 14, 2008 Brian Lawler	Worst Stock for 2008: Pfizer This analyst thinks that Pfizer is a good company, but a bad stock for 2008.
The Motley Fool August 4, 2009 Matt Koppenheffer	How Long Should You Ride This Rally? This rally in the market has been a great ride, but is it time to hop off?
The Motley Fool March 2, 2011 Dan Caplinger	A Better Place to Find Great Value Stocks Look beyond the megacaps.
The Motley Fool May 12, 2010 Matt Koppenheffer	Are Health-Care Stocks a Buy? Health-care stocks have underperformed the market so far this year. Is it time for a turnaround?
The Motley Fool January 24, 2010 Matt Koppenheffer	How Long Should You Ride This Rally? This rally has been a great ride, but is it time to hop off?
The Motley Fool March 2, 2010 Dan Caplinger	These 5 Winners Are Still Great Values Not all value stocks are down and out. Going forward, it'll take a little digging to find stocks that are good values.
The Motley Fool February 20, 2010 Matt Koppenheffer	How Long Should You Ride This Rally? This rally has been a great ride, but is it time to hop off?
The Motley Fool August 3, 2007 Rich Duprey	The Only 3 Ideas You Need Instead of buying insanely valued stocks at a premium, we should be looking at deeply discounted stocks that the market has tossed aside.
The Motley Fool December 18, 2008 Brian Orelli	Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009.
The Motley Fool April 21, 2004 Ben McClure	Discount Pharmacy With prices beaten down across the pharmaceuticals industry and the quarterly reporting season here, do any investment opportunities pop up?
The Motley Fool August 9, 2011 Eric Bleeker	Rising Star Buy: EMC Is a Steal The storage leader keeps delivering, and keeps getting cheaper.
Registered Rep. August 10, 2010 David A. Geracioti	Not Every Recovery Looks the Same, a Q&A with a Bullish Value Manager Registered Rep. editor sat down for lunch with Craig Callahan, ICON Advisors founder and president, to get his quant-influenced and very often contrarian views on the stock market.
Financial Advisor August 2006 Marla Brill	Theme Reversal Or Head Fake? ICON International Equity Fund manager eyes a move toward defensive industries.
The Motley Fool December 20, 2010 Dan Caplinger	2 Smart Sectors for 2011 Are beaten-down sector ETFs the best bets?
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear Rebuttal Generic competition for Lipitor is just the beginning. Faith is nice in terms of religion, but when it comes to investments, investors need to be able to make some reasonable assumptions about future growth plans.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull Rebuttal The patent expirations are an issue, but the cash is what's really important. Investors, take note.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Mixed Foliage at Forest Labs Here's what to look for as Forest Labs prepares for a big loss. Investors, take note.
The Motley Fool June 8, 2004 Shannon Zimmerman	The Case for Mutual Funds Our resident fund jockey takes on all doubters. Are mutual funds a good investment, or just a way to underperform?
The Motley Fool September 9, 2009 Jennifer Schonberger	Expert Summit: Are Stocks Still Undervalued? Valuations look expensive based on this year, but next year looks better.
The Motley Fool October 11, 2004 Roger Nusbaum	Pfizer: Prognosis Critical This American icon seems destined to lag for the forseeable future.
The Motley Fool August 3, 2011 Brian Orelli	Ignore Pfizer's Financials for Now It's the pipeline that matters.
The Motley Fool June 9, 2006 Nathan Parmelee	Are You Prepared for Volatility? Investors, here's how to use the market's ups and downs to your advantage.
The Motley Fool November 7, 2011 Dan Caplinger	Has Pfizer Become the Perfect Stock? The pharma giant still faces the challenge of patent expirations that could outpace its pipeline development.
The Motley Fool March 22, 2010 Matt Koppenheffer	How Long Should You Ride This Rally? This rally has been a great ride, but is it time to hop off? Our concern shouldn't be how much the market has gone up or down, but rather whether its valuation is attractive or unattractive.
Registered Rep. March 1, 2005 David A. Twibell	What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in.
Financial Planning December 1, 2005	Are Equities Undervalued? Given the risks that exist, analysts aren't planning to overweight equities at this time. But a decline in prices could make a compelling opportunity for a tactical overweight in stocks.
The Motley Fool February 22, 2005 Charly Travers	Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list.
BusinessWeek September 23, 2010	The Other Oracle of Omaha Speaks Wally Weitz scouts for broken growth stocks, arbitrage plays, and underappreciated small caps.
The Motley Fool April 24, 2009 Dan Caplinger	Don't Get Trapped by False Value Stocks Do you trust the books?
The Motley Fool November 20, 2009 Dan Caplinger	7 Stocks That Give You Real Value Now that the rally has pushed share prices back up to somewhat pricier levels, you can't afford to get stuck with stocks that turn out to be value traps. Take a look at 7 real-value stocks.
The Motley Fool January 19, 2005 Stephen D. Simpson	Pfizer Doesn't Give Much Fizz The company reports mediocre earnings as investors remain nervous about the drug sector.
The Motley Fool March 3, 2011 Amanda B. Kish	A Red Hot Sector Play for 2011 I think there are several sectors that should do well in 2011, including financials and health care, but the one I'm most excited about is information technology. Mutual funds are the way to go.
The Motley Fool September 11, 2007 Brian Lawler	Looking Forward at Pfizer With generic competition on the way for Pfizer's top drug, Lipitor, the company stepped up to the podium at the Bear Stearns Healthcare Conference this week to let investors know its plans.
The Motley Fool August 9, 2010 Alex Dumortier	Top 5 Banks: Long-Term Buy or Short-Term Sell? Banks are prepared for a slowdown. Are you?
The Motley Fool October 21, 2009 Dan Caplinger	These 5 Stocks Aren't As Cheap as They Look Don't be misled by the attractive valuations of these stocks: Cardinal Health... Discover... Sunoco... U.S. Steel... Tenet Healthcare...
Registered Rep. January 1, 2007 Craig T. Callahan	Rave On, Mister Market The bull is back and on a tear. Most market indices hit a low on March 11, 2003. Since then, they've been on a three-year run, hitting a peak on May 5, 2006. Which industries and sectors will lead the market over the next year?
The Motley Fool March 18, 2009 Todd Wenning	How to Profit From Fear You can protect your downside risk by buying put options on the stocks you own. A put option gives you the right to sell your stock at a certain price by a certain time.
The Motley Fool January 23, 2007 Ryan Fuhrmann	Pfizer Pfizzles Through 2006 The company is in a top-line pickle, but it expects things to get better. Current investors are now left standing until a rebound in growth, now targeted for 2009.
AskMen.com October 8, 2000 Ric Poupada	Computer Stock Prices Go Down Fortunately, every investor's portfolio is taking a nose dive, so the fact that a monkey could have picked stocks better than me so far this year doesn't make me feel too inferior...
The Motley Fool November 7, 2006 Matt Koppenheffer	Dell's Dull, Dude! The computer market isn't what it used to be, but Dell is finding other ways to grow and still does PCs pretty well. With a recent upgrade from a Goldman Sachs analyst, the stock is now officially a turnaround candidate.
BusinessWeek September 24, 2009 Spencer E. Ante	Tech: The Return of Risk-Taking Suddenly, there are mergers and acquisitions, IPOs, and investors galore. Will the reenergized industry lead the U.S. out of the Great Recession?
The Motley Fool December 22, 2009 Matt Koppenheffer	How Long Should You Ride This Rally? Our concern shouldn't be how much the market has gone up or down, but rather whether its valuation is attractive or unattractive.
Bio-IT World February 11, 2005 Prashant Tyagi	Can Life Sciences Go the IT Way? Guest commentary: lessons for guiding the revolution in biotechnology and other life science disciplines.
The Motley Fool February 28, 2005 Salim Haji	Why Value Trumps Growth Growth vs. value: This author works it out and comes up with a definitive answer. Obviously, the best possible investment is a combination -- buying a growth stock at a discount to intrinsic value.
The Motley Fool September 10, 2009 Jennifer Schonberger	Expert Summit: How to Invest Right Now Top financial experts on their favorite sectors and companies.
The Motley Fool January 12, 2010 Matt Koppenheffer	Will Earnings Season Make Stocks Look Cheap? Earnings season is upon us, but will it give us reason to buy? This year's fourth-quarter earnings season should bear little resemblance to last year's.
The Motley Fool October 13, 2008 Dan Caplinger	What Are Your Stocks Really Worth? Stop flying blind or your portfolio could end up on the side of a mountain.